<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39013199</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2463-0225</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Revista colombiana de obstetricia y ginecologia</Title><ISOAbbreviation>Rev Colomb Obstet Ginecol</ISOAbbreviation></Journal><ArticleTitle>Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4094</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.18597/rcog.4094</ELocationID><Abstract><AbstractText>Introduction and objective: The approach to patients with advanced or metastatic high-grade epithelial ovarian cancer (EOC) has evolved over time with the advent of new therapies and multimodal strategies. The objective of this consensus of experts is to generate national recommendations for the profiling and management of advanced or metastatic high-grade OEC, defined as stages III and IV of the &#x201c;The International Federation of Gynecology and Obstetrics (FIGO) classification at the time of diagnosis to base on the literature review that included international evidence-based clinical practice guidelines (CPG). Material and methods: Eleven panelists (oncologists and gynecological oncologists) answered 8 questions about the profiling and management of advanced or metastatic ovarian epithelial carcinoma. The panelists were chosen for their academic profile and influence in national health institutions. Guidelines from the &#x201c;ESMO Standardized Operating Procedures Consensus Conference&#x201d; were used to develop the consensus. It was agreed that the level of agreement to accept a recommendation should be &#x2265; 80%. The document was peer reviewed. Results: Eight general recommendations are made, which are presented into five domains. Some of these recommendations are subdivided into specific recommendations. Initial treatment Recommendation 1.1 Complete primary cytoreduction (PCS) surgery is suggested as the initial therapy of choice for patients with high-grade or metastatic EOC, which should ideally be carried out in centers with experience, followed by adjuvant therapy. 1.2 Neoadjuvant chemotherapy followed by interval cytoreduction surgery (ICS) is suggested in those who are unlikely to achieve a complete cytoreduction in PCS either due to unresectable metastatic disease or who present unresectability criteria (imaging, laparoscopic and/or by laparotomy) and that have been defined by a gynecological oncologist and patients with poor functional status and comorbidities according to the criteria of the multidisciplinary team (clinical oncology, gynecological oncology, radiology, etc.). Recommendation 2. In patients with high-grade epithelial ovarian cancer (EOC), in stage III locally advanced or metastatic, who received neoadjuvant chemotherapy and achieved a complete or partial response (cytoreduction with tumor residue &lt; 2.5 mm), the use of Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) could be considered as an alternative to standard platinum-based adjuvant intravenous chemotherapy during interval cytoreductive surgery, after discussion in a multidisciplinary tumor board, at a center experienced in treating this type of patients. Use of genetic testing. Recommendation 3. It is suggested at the time of diagnosis to offer molecular genetic testing to all patients with high-grade advanced or metastatic EOC regardless of family history. Recommendation 4. It is suggested to offer genetic counseling, by qualified personnel, to all patients with high-grade advanced or metastatic EOC who are ordered genetic testing. Recommendation 5. It is suggested that all patients with advanced or metastatic high-grade EOC undergo a germ panel that includes the Breast Cancer Susceptibility Genes 1/2 genes (BRCA 1/2) and the other susceptibility genes according to with institutional protocols and the availability of genetic testing panels; If it is negative, then somatic testing should be performed that includes the homologous recombination deficiency (HRD) status, regardless of family history. Adjuvant Therapy Recommendation 6. 6.1. It is suggested that all patients with advanced stage III/IV EOC, with PSC of (0-2), got adjuvant intravenous chemotherapy as standard treatment within six weeks after Prc. It is suggested paclitaxel/carboplatin. Recommendation 6.2. It is suggested to use standard chemotherapy base on platinum plus Bevacizumab as adjuvant chemotherapy to patients with high-risk disease (EOC stage IV or stage III with suboptimal tumor cytoreduction), following by bevacizumab as maintenance. The use of bevacizumab as maintenance therapy is not recommended if bevacizumab was not included in the first line of treatment. We suggested the dose used in GOG-0218 and ICON7 trials. Recommendation 6.3 It is suggested combined intravenous/intraperitoneal chemotherapy only for selected patients, with optimal cytoreduction (residual lesions &lt; 1 cm), especially those without residual disease (R0) and who are evaluated in a multidisciplinary meeting. It is not considered standard treatment. Recommendation 6.4. 6.4.1 It is suggested to use Poly ADP ribose polymerase (PARP) inhibitors such as olaparib or niraparib as maintenance after receiving first-line chemotherapy in patients with stage III/IV BRCA1/2 positive EOC who received platinumbased chemotherapy and obtained complete response/partial response (CR/PR), 6.4.2 It is suggested to use olaparib alone or in combination with bevacizumab or niraparib in patients with stage III/IV BRCA1/2 positive EOC who received platinum-based chemotherapy plus bevacizumab and achieved CR/PR. 6.4.3 It is suggested to use niraparibin patients with stage III/IV BRCA1/2 negative or unknown EOC who received platinum-based chemotherapy and achieved CR/PR. 6.4.4 It is suggested to use bevacizumab or olaparib plus bevacizumab in patients with EOC stage III/IV BRCA1/2 negative or unknown (HRD positive) who received platinum-based chemotherapy plus bevacizumab and obtained CR/PR. Treatment of disease relapse Recommendation 7. Secondary cytoreductive surgery followed by chemotherapy is suggested for selected patients with high-grade advanced EOC in first relapse, platinum-sensitive (platinum-free interval &#x2265; 6 months), positive &#x201c;Arbeitsgemeinschaft Gyn&#xe4;kologische Onkologie &#x2013; AGO&#x201d; score or &#x201c;I-model&#x201d; positive (&lt; 4.7) with a potential resection to R0 in centers with access to optimal surgical and postoperative support. Note: Platinum-free interval and AGO score have only been developed as positive predictors of complete resection and not to exclude patients from surgery. Recommendation 8. 8.1 For patients with relapse advanced high-grade EOC platinum-sensitive, the following is suggested: Platinum-based combination chemotherapy: carboplatin/liposomal doxorubicin or carboplatin/paclitaxel or carboplatin/nab-paclitaxel or carboplatin/docetaxel or carboplatin/gemcitabine) for six cycles. If combination therapy is not tolerated, give carboplatin or cisplatin alone. Combination chemotherapy (carboplatin/gemcitabine or carboplatin/paclitaxel or carboplatin/doxorubicin liposomal) plus bevacizumab followed by bevacizumab as maintenance (until progression or toxicity). Recommendation 8.2 For patients with relapsed advanced high-grade EOC platinum-resistant, it is suggested: Sequential treatment with chemotherapy, preferably with a non-platinum single agent (weekly paclitaxel or pegylated liposomal doxorubicin or docetaxel or oral etoposide or gemcitabine or trabectidine or, topotecan). Weekly paclitaxel or pegylated liposomal doxorubicin or topotecan could be administrate with or without bevacizumab. Other agents are considered potentially active (capecitabine, cyclophosphamide, ifosfamide, irinotecan, oxaliplatin, pemetrexed, vinorelbine, cyclophosphamide) could be recommended for later lines. Hormone receptor-positive patients who do not tolerate or have no response to cytotoxic regimens may receive hormone therapy with tamoxifen or other agents, including aromatase inhibitors (anastrozole and letrozole) or leuprolide acetate, or megestrol acetate. Patients with a performance score &#x2265; 3 should be considered only for best supportive care. Recommendation 8.3 Maintenance therapy with PARP inhibitors: It is suggested in patients with relapse advanced high-grade EOC stage III/IV BRCA1/2 (positive, negative or unknown) who have received two or more lines of platinum-based chemotherapy and have achieved CR/PR, use olaparib, niraparib or rucaparib. Niraparib could be useful in BRCA 1/2 +/-/unknown patients, as rucaparib, however, the latter does not yet have approval from the regulatory office in Colombia. Conclusions: It is expected that the recommendations issued in this consensus will contribute to improving clinical care, oncological impact, and quality of life of these women.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pierre</LastName><ForeName>Marc E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0003-2119-9840</Identifier><AffiliationInfo><Affiliation>Centro de tratamiento e investigaci&#xf3;n sobre el C&#xe1;ncer Luis Carlos Sarmiento (CTIC), Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manneh</LastName><ForeName>Ray</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8106-9741</Identifier><AffiliationInfo><Affiliation>Sociedad de Oncolog&#xed;a y Hematolog&#xed;a del Cesar, Valledupar, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Abraham</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0258-5888</Identifier><AffiliationInfo><Affiliation>Centro hospitalario Serena del Mar, Cartagena, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5472-4093</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3;n Santaf&#xe9; de Bogot&#xe1;, Bogot&#xe1;, Colombia. Departamento de obstetricia y ginecolog&#xed;a Universidad Nacional de Colombia, Bogot&#xe1;, Colombia. Instituto Nacional de Cancerolog&#xed;a, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Ang&#xe9;lica V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0001-8634-6261</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Oncol&#xf3;gicas Cl&#xed;nica San Diego (CIOSAD), Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez</LastName><ForeName>Heydi M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0001-9928-811X</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3;n Valle de Lili, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni&#xf1;o</LastName><ForeName>Oscar M</ForeName><Initials>OM</Initials><Identifier Source="ORCID">0000-0002-2138-5144</Identifier><AffiliationInfo><Affiliation>Hospital San Ignacio, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez</LastName><ForeName>Diego A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-4376-4583</Identifier><AffiliationInfo><Affiliation>Hospital Internacional de Colombia, Bucaramanga, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanabria</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2258-6546</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3;n Santaf&#xe9; de Bogot&#xe1;, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contreras</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1859-5906</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Cancerolog&#xed;a, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieschac&#xf3;n</LastName><ForeName>Jos&#xe9; R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0003-2363-7373</Identifier><AffiliationInfo><Affiliation>Evidentias SAS, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calder&#xf3;n</LastName><ForeName>Pedro H</ForeName><Initials>PH</Initials><Identifier Source="ORCID">0000-0003-3672-4820</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Cancerolog&#xed;a, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><VernacularTitle>Consenso de expertos basado en la evidencia: perfilamiento y manejo del carcinoma epitelial de ovario de alto grado avanzado.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Rev Colomb Obstet Ginecol</MedlineTA><NlmUniqueID>0404263</NlmUniqueID><ISSNLinking>0034-7434</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="Y">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077216" MajorTopicYN="Y">Carcinoma, Ovarian Epithelial</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065426" MajorTopicYN="N">Cytoreduction Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009375" MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Introducci&#xf3;n y objetivo: el abordaje de pacientes con c&#xe1;ncer epitelial de ovario (CEO) de alto grado avanzado o metast&#xe1;sico ha ido evolucionando a trav&#xe9;s del tiempo con el advenimiento de nuevas terapias y estrategias multimodales. El objetivo de este consenso de expertos es generar recomendaciones nacionales para el perfilamiento y manejo del CEO de alto grado avanzado o metast&#xe1;sico, definido como estadios III y IV de la clasificaci&#xf3;n de la Federaci&#xf3;n Internacional de Ginecolog&#xed;a y Obstetricia (FIGO) al momento del diagn&#xf3;stico, a partir de la revisi&#xf3;n de la literatura que incluy&#xf3; gu&#xed;as de pr&#xe1;ctica cl&#xed;nica (GPC) internacionales basadas en la evidencia. Materiales y m&#xe9;todos: once panelistas (onc&#xf3;logos y ginec&#xf3;logos onc&#xf3;logos) respondieron ocho preguntas sobre el perfilamiento y manejo del carcinoma epitelial de ovario avanzado o metast&#xe1;sico. Los panelistas fueron escogidos por su perfil acad&#xe9;mico e influencia en instituciones de salud nacionales. Para el desarrollo del consenso se utilizaron los lineamientos de la &#x201c;Conferencia de consenso de procedimientos operativos estandarizados de ESMO&#x201d;. Se defini&#xf3; que el nivel de acuerdo para aceptar una recomendaci&#xf3;n deb&#xed;a ser &#x2265; 80%. El documento fue revisado por pares. Resultados: Se hacen 8 recomendaciones generales, presentadas en cinco dominios; algunas de ellas se subdividen en recomendaciones espec&#xed;ficas. Tratamiento inicial Recomendaci&#xf3;n 1 1.1. Como terapia inicial de elecci&#xf3;n para pacientes con CEO de alto grado o metast&#xe1;sico se sugiere la cirug&#xed;a de citorreducci&#xf3;n primaria (Cpr) completa que, idealmente, debe realizarse en centros con experiencia, seguida de terapia adyuvante. 1.2. Se sugiere quimioterapia neoadyuvante seguida de cirug&#xed;a de citorreducci&#xf3;n de intervalo (Cint) en quienes sea improbable alcanzar una citorreducci&#xf3;n completa en la Cpr, bien sea por enfermedad metast&#xe1;sica no resecable o que presenten criterios de irresecabilidad (imagenol&#xf3;gicos, laparosc&#xf3;picos o por laparotom&#xed;a) que hayan sido definidos por un ginec&#xf3;logo onc&#xf3;logo. Tambi&#xe9;n en pacientes con un pobre estado funcional y comorbilidades de acuerdo con el criterio del equipo multidisciplinario (oncolog&#xed;a cl&#xed;nica, ginecolog&#xed;a oncol&#xf3;gica, radiolog&#xed;a, etc.). Recomendaci&#xf3;n 2. En pacientes con CEO de alto grado, en estadio III localmente avanzado o metast&#xe1;sico, que recibieron quimioterapia neoadyuvante y alcanzaron respuesta completa o parcial (citorreducci&#xf3;n con residuo tumoral &lt; 2,5 mm), se podr&#xed;a evaluar el uso de la quimioterapia intraperitoneal hipert&#xe9;rmica (Hyperthermic IntraPeritoneal Chemotherapy - HIPEC) como alternativa a la quimioterapia IV adyuvante est&#xe1;ndar basada en platinos durante la Cint, previa discusi&#xf3;n en junta multidisciplinaria, en un centro de experiencia en este tipo de pacientes. Uso de pruebas gen&#xe9;ticas Recomendaci&#xf3;n 3. Al momento del diagn&#xf3;stico, se sugiere ofrecer testeo molecular gen&#xe9;tico a toda paciente con CEO de alto grado avanzado o metast&#xe1;sico, independientemente de la historia familiar. Recomendaci&#xf3;n 4. Se sugiere ofrecer asesoramiento gen&#xe9;tico, por parte de personal calificado, a toda paciente con CEO de alto grado avanzado o metast&#xe1;sico a quien se le ordene un testeo gen&#xe9;tico. Recomendaci&#xf3;n 5. Se sugiere que a toda paciente con CEO de alto grado avanzado o metast&#xe1;sico se le realice panel germinal que incluya los genes de susceptibilidad al c&#xe1;ncer de mama 1/2 (BRCA 1/2) y los otros genes de susceptibilidad de acuerdo con los protocolos institucionales y la disponibilidad de paneles de testeo gen&#xe9;tico; si es negativo entonces se deber&#xed;a realizar testeo som&#xe1;tico que incluya el estatus de deficiencia de la recombinaci&#xf3;n hom&#xf3;loga (homologous recombination deficiency - HRD), independientemente de la historia familiar. Terapia adyuvante Recomendaci&#xf3;n 6 6.1. Se sugiere que a toda paciente con CEO estadios III/IV avanzado o metast&#xe1;sico, con estatus de desempe&#xf1;o (performance score care - PSC) de 0-2 se le administre como tratamiento est&#xe1;ndar quimioterapia intravenosa (IV) adyuvante dentro de las seis semanas posteriores a la Cpr. Se sugiere administrar paclitaxel/carboplatino. 6.2. Se sugiere utilizar quimioterapia est&#xe1;ndar basada en platino m&#xe1;s bevacizumab como adyuvancia en pacientes con enfermedad de alto riesgo (CEO estadios IV o III con citorreducci&#xf3;n tumoral sub&#xf3;ptima), continuando con bevacizumab como mantenimiento. No se recomienda el uso de bevacizumab como terapia de mantenimiento si no se incluy&#xf3; en la primera l&#xed;nea de tratamiento. Se sugiere seguir los esquemas de los estudios Gynecologic Oncology Group Study (GOG-0218) e International Collaborative Ovarian Neoplasm (ICON7). 6.3. Se sugiere la quimioterapia combinada IV/intraperitoneal (IP) solo para pacientes seleccionadas, con una citorreducci&#xf3;n &#xf3;ptima (lesiones residuales &lt; 1 cm), en especial aquellas sin enfermedad residual (R0) y que sean evaluadas en junta multidisciplinaria. La quimioterapia combinada IV/IP no se considera como tratamiento est&#xe1;ndar. 6.4. 6.4.1. Se sugiere utilizar inhibidores de poli(ADP-ribosa) polimerasa (PARP) tales como olaparib o niraparib como mantenimiento despu&#xe9;s de recibir una primera l&#xed;nea de quimioterapia en pacientes con CEO estadios III/IV BRCA1/2 positivo que recibieron quimioterapia basada en platino y obtuvieron respuesta completa/respuesta parcial (RC/RP). 6.4.2. Se sugiere utilizar olaparib solo o en combinaci&#xf3;n con bevacizumab o niraparib en pacientes con CEO estadios III/IV BRCA1/2 positivo que recibieron quimioterapia basada en platino m&#xe1;s bevacizumab y obtuvieron RC/RP. 6.4.3. Se sugiere utilizar niraparib en pacientes con CEO estadio III/IV BRCA1/2 negativo o desconocido que recibieron quimioterapia basada en platino y obtuvieron RC/RP. 6.4.4. Se sugiere utilizar bevacizumab u olaparib m&#xe1;s bevacizumab en pacientes con CEO estadios III/IV BRCA1/2 negativo o desconocido (HRD positivo) que recibieron quimioterapia basada en platino m&#xe1;s bevacizumab y obtuvieron RC/RP. Tratamiento de la reca&#xed;da de la enfermedad Recomendaci&#xf3;n 7. Se sugiere la realizaci&#xf3;n de la cirug&#xed;a de citorreducci&#xf3;n secundaria (Csec), seguida de quimioterapia, a pacientes seleccionadas con CEO de alto grado avanzado o metast&#xe1;sico en primera reca&#xed;da, platino-sensibles (intervalo libre de platinos &#x2265; 6 meses), puntuaci&#xf3;n Arbeitsgemeinschaft Gyn&#xe4;kologische Onkologie (AGO) positiva o Integrate model (I-Model) positivo (&lt; 4,7), y con una potencial resecci&#xf3;n a R0, en centros con acceso a soporte quir&#xfa;rgico y posoperatorio &#xf3;ptimo. Nota: el intervalo libre de tratamiento con platinos y la puntuaci&#xf3;n AGO solo se han desarrollado como predictores positivos de resecci&#xf3;n completa y no para excluir a las pacientes de la cirug&#xed;a. Recomendaci&#xf3;n 8 8.1. Para pacientes con CEO de alto grado avanzado o metast&#xe1;sico en reca&#xed;da platino-sensibles se sugiere: Quimioterapia combinada basada en platino: carboplatino/doxorrubicina liposomal o carboplatino/paclitaxel o carboplatino/ nab-paclitaxel o carboplatino/docetaxel o carboplatino/gemcitabina, por seis ciclos. Si no se tolera la terapia combinada, dar carboplatino o cisplatino solo. Quimioterapia combinada: carboplatino/gemcitabina o carboplatino/paclitaxel o carboplatino/doxorubicina liposomal, m&#xe1;s bevacizumab, seguida de bevacizumab como mantenimiento (hasta progresi&#xf3;n o toxicidad). 8.2. Para pacientes con CEO de alto grado avanzado o metast&#xe1;sico en reca&#xed;da, platino-resistentes, se sugiere: Tratamiento secuencial con quimioterapia, preferiblemente con un agente &#xfa;nico que no sea un platino (paclitaxel semanal o doxorrubicina liposomal pegilada o docetaxel o etop&#xf3;sido oral o gemcitabina o trabectidina o topotecan). El paclitaxel semanal o la doxorrubicina liposomal pegilada o el topotecan pueden ser administrados con o sin bevacizumab. Existen otros agentes que se consideran potencialmente act ivos (capecitabina, ciclofosfamida, ifosfamida, irinotec&#xe1;n, oxaliplatino, pemetrexed, vinorelbina, ciclofosfamida), que se podr&#xed;an recomendar para l&#xed;neas posteriores. Las pacientes con receptores hormonales positivos que no toleran o no tienen respuesta a los reg&#xed;menes citot&#xf3;xicos pueden recibir terapia hormonal con tamoxifeno u otros agentes, incluidos los inhibidores de la aromatasa (anastrozol y letrozol) o acetato de leuprolide o acetato de megestrol. Pacientes con PSC &#x2265; 3 deber&#xed;an ser consideradas solo para el mejor cuidado de soporte. 8.3. Terapia de mantenimiento con inhibidores PARP. Para pacientes con CEO de alto grado avanzado o metast&#xe1;sico en reca&#xed;da estadios III/IV BRCA1/2 (positivo, negativo o desconocido), que hayan recibido dos o m&#xe1;s l&#xed;neas de quimioterapia basada en platino y hayan alcanzado RC/RP, se sugiere utilizar olaparib, niraparib o rucaparib. El niraparib podr&#xed;a ser &#xfa;til en pacientes BRCA 1/2 +/-/desconocido, al igual que el rucaparib, sin embargo, este &#xfa;ltimo no tiene a&#xfa;n aprobaci&#xf3;n del ente regulador en Colombia. Conclusiones: se espera que las recomendaciones emitidas en este consenso contribuyan a mejorar la atenci&#xf3;n cl&#xed;nica, el impacto oncol&#xf3;gico y la calidad de vida de estas mujeres.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="eng"><AbstractText Label="INTRODUCTION AND OBJECTIVE:">The approach to patients with advanced or metastatic high-grade epithelial ovarian cancer (EOC) has evolved over time with the advent of new therapies and multimodal strategies. The objective of this consensus of experts is to generate national recommendations for the profiling and management of advanced or metastatic high-grade OEC, defined as stages III and IV of the "The International Federation of Gynecology and Obstetrics (FIGO) classification at the time of diagnosis to base on the literature review that included international evidence-based clinical practice guidelines (CPG).</AbstractText><AbstractText Label="MATERIAL AND METHODS:">Eleven panelists (oncologists and gynecological oncologists) answered 8 questions about the profiling and management of advanced or metastatic ovarian epithelial carcinoma. The panelists were chosen for their academic profile and influence in national health institutions. Guidelines from the "ESMO Standardized Operating Procedures Consensus Conference" were used to develop the consensus. It was agreed that the level of agreement to accept a recommendation should be &gt; 80%. The document was peer reviewed.</AbstractText><AbstractText Label="RESULTS:">Eight general recommendations are made, which are presented into five domains. Some of these recommendations are subdivided into specific recommendations. <i>Initial treatment</i> Recommendation 1.1 Complete primary cytoreduction (PCS) surgery is suggested as the initial therapy of choice for patients with high-grade or metastatic EOC, which should ideally be carried out in centers with experience, followed by adjuvant therapy. 1.2 Neoadjuvant chemotherapy followed by interval cytoreduction surgery (ICS) is suggested in those who are unlikely to achieve a complete cytoreduction in PCS either due to unresectable metastatic disease or who present unresectability criteria (imaging, laparoscopic and/or by laparotomy) and that have been defined by a gynecological oncologist and patients with poor functional status and comorbidities according to the criteria of the multidisciplinary team (clinical oncology, gynecological oncology, radiology, etc.). <i>Recommendation 2.</i> In patients with high-grade epithelial ovarian cancer (EOC), in stage III locally advanced or metastatic, who received neoadjuvant chemotherapy and achieved a complete or partial response (cytoreduction with tumor residue &lt; 2.5 mm), the use of Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) could be considered as an alternative to standard platinum-based adjuvant intravenous chemotherapy during interval cytoreductive surgery, after discussion in a multidisciplinary tumor board, at a center experienced in treating this type of patients. Use of genetic testing. <i>Recommendation 3.</i> It is suggested at the time of diagnosis to offer molecular genetic testing to all patients with high-grade advanced or metastatic EOC regardless of family history. <i>Recommendation 4.</i> It is suggested to offer genetic counseling, by qualified personnel, to all patients with high-grade advanced or metastatic EOC who are ordered genetic testing. <i>Recommendation 5.</i> It is suggested that all patients with advanced or metastatic high-grade EOC undergo a germ panel that includes the Breast Cancer Susceptibility Genes 1/2 genes (BRCA 1/2) and the other susceptibility genes according to with institutional protocols and the availability of genetic testing panels; If it is negative, then somatic testing should be performed that includes the homologous recombination deficiency (HRD) status, regardless of family history. <i>Adjuvant Therapy</i> <i>Recommendation 6.</i> 6.1. It is suggested that all patients with advanced stage III/IV EOC, with PSC of (0-2), got adjuvant intravenous chemotherapy as standard treatment within six weeks after Prc. It is suggested paclitaxel/carboplatin. <i>Recommendation 6.2.</i> It is suggested to use standard chemotherapy base on platinum plus Bevacizumab as adjuvant chemotherapy to patients with high-risk disease (EOC stage IV or stage III with suboptimal tumor cytoreduction), following by bevacizumab as maintenance. The use of bevacizumab as maintenance therapy is not recommended if bevacizumab was not included in the first line of treatment. We suggested the dose used in GOG-0218 and ICON7 trials. <i>Recommendation 6.3</i> It is suggested combined intravenous/intraperitoneal chemotherapy only for selected patients, with optimal cytoreduction (residual lesions &lt; 1 cm), especially those without residual disease (R0) and who are evaluated in a multidisciplinary meeting. It is not considered standard treatment. <i>Recommendation 6.4.</i> 6.4.1 It is suggested to use Poly ADP ribose polymerase (PARP) inhibitors such as olaparib or niraparib as maintenance after receiving first-line chemotherapy in patients with stage III/ IV BRCA1/2 positive EOC who received platinum-based chemotherapy and obtained complete response/ partial response (CR/PR), 6.4.2 It is suggested to use olaparib alone or in combination with bevacizumab or niraparib in patients with stage III/IV BRCA1/2 positive EOC who received platinum-based chemotherapy plus bevacizumab and achieved CR/PR. 6.4.3 It is suggested to use niraparibin patients with stage III/IV BRCA1/2 negative or unknown EOC who received platinum-based chemotherapy and achieved CR/PR, 6.4.4 It is suggested to use bevacizumab or olaparib plus bevacizumab in patients with EOC stage III/ IV BRCA1/2 negative or unknown (HRD positive) who received platinum-based chemotherapy plus bevacizumab and obtained CR/PR. <i>Treatment of disease relapse</i> <i>Recommendation 7.</i> Secondary cytoreductive surgery followed by chemotherapy is suggested for selected patients with high-grade advanced EOC in first relapse, platinum-sensitive (platinum-free interval &gt; 6 months), positive "Arbeitsgemeinschaft Gyn&#xe4;kologische Onkologie - AGO" score or "I-model" positive (&lt; 4.7) with a potential resection to R0 in centers with access to optimal surgical and postoperative support. Note: Platinum-free interval and AGO score have only been developed as positive predictors of complete resection and not to exclude patients from surgery. <i>Recommendation 8.</i> 8.1 For patients with relapse advanced high-grade EOC platinum-sensitive, the following is suggested: &#x2022; Platinum-based combination chemotherapy: carboplatin/liposomal doxorubicin or carboplatin/ paclitaxel or carboplatin/nab-paclitaxel or carboplatin/docetaxel or carboplatin/gemcitabine) for six cycles. If combination therapy is not tolerated, give carboplatin or cisplatin alone. &#x2022; Combination chemotherapy (carboplatin/ gemcitabine or carboplatin/paclitaxel or carboplatin/doxorubicin liposomal) plus bevacizumab followed by bevacizumab as maintenance (until progression or toxicity). <i>Recommendation 8.2</i> For patients with relapsed advanced high-grade EOC platinum-resistant, it is suggested: &#x2022; Sequential treatment with chemotherapy, preferably with a non-platinum single agent (weekly paclitaxel or pegylated liposomal doxorubicin or docetaxel or oral etoposide or gemcitabine or trabectidine or, topotecan). Weekly paclitaxel or pegylated liposomal doxorubicin or topotecan could be administrate with or without bevacizumab. &#x2022; Other agents are considered potentially active (capecitabine, cyclophosphamide, ifosfamide, irinotecan, oxaliplatin, pemetrexed, vinorelbine, cyclophosphamide) could be recommended for later lines. &#x2022; Hormone receptor-positive patients who do not tolerate or have no response to cytotoxic regimens may receive hormone therapy with tamoxifen or other agents, including aromatase inhibitors (anastrozole and letrozole) or leuprolide acetate, or megestrol acetate. &#x2022; Patients with a performance score &gt; 3 should be considered only for best supportive care. <i>Recommendation 8.3</i> Maintenance therapy with PARP inhibitors: It is suggested in patients with relapse advanced high-grade EOC stage III/IV BRCA1/2 (positive, negative or unknown) who have received two or more lines of platinum-based chemotherapy and have achieved CR/PR, use olaparib, niraparib or rucaparib. Niraparib could be useful in BRCA &#xbd; +/-/unknown patients, as rucaparib, however, the latter does not yet have approval from the regulatory office in Colombia.</AbstractText><AbstractText Label="CONCLUSIONS:">It is expected that the recommendations issued in this consensus will contribute to improving clinical care, oncological impact, and quality of life of these women.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Carcinoma</Keyword><Keyword MajorTopicYN="N">ovarian epithelial</Keyword><Keyword MajorTopicYN="N">cytoreduction surgical procedures</Keyword><Keyword MajorTopicYN="N">chemotherapy</Keyword><Keyword MajorTopicYN="N">adjuvant</Keyword><Keyword MajorTopicYN="N">hyperthermic intraperitoneal chemotherapy</Keyword><Keyword MajorTopicYN="N">genetic counseling</Keyword><Keyword MajorTopicYN="N">consensus</Keyword><Keyword MajorTopicYN="N">Poly (ADP-Ribose) Polymerase-1</Keyword></KeywordList><CoiStatement><b>Conflicto de intereses:</b> la declaraci&#xf3;n de conflictos de inter&#xe9;s de cada uno de los miembros del consenso se realiz&#xf3; desde el inicio del proceso. Ning&#xfa;n miembro del panel estuvo inhabilitado para votar las recomendaciones por conflictos de inter&#xe9;s. El doctor AF recibi&#xf3; apoyo para asistir a cenas de trabajo y para participar en un consenso de parte de AstraZeneca; el doctor AH recibi&#xf3; apoyo para asistir a reuniones acad&#xe9;micas y recibi&#xf3; honorarios por actuar como ponente de parte de AstraZeneca; el doctor DG recibi&#xf3; apoyo para asistir a reuniones acad&#xe9;micas organizadas por AstraZeneca, recibi&#xf3; honorarios por actuar como ponente, recibi&#xf3; apoyo y financiaci&#xf3;n para proyectos de investigaci&#xf3;n y recibi&#xf3; apoyo para cursar programas acad&#xe9;micos por parte de AstraZeneca; el doctor HR. recibi&#xf3; apoyo para asistir a reuniones acad&#xe9;micas y financiaci&#xf3;n para proyectos de investigaci&#xf3;n por parte de AstraZeneca; el doctor RP. recibe honorarios como consultor de AstraZeneca por lo cual no hizo parte de ninguna de las votaciones de las recomendaciones.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>16</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>16</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>16</Day><Hour>17</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39013199</ArticleId><ArticleId IdType="pmc">PMC11210286</ArticleId><ArticleId IdType="doi">10.18597/rcog.4094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Global Cancer Obser vator y. GLOBOCAN  . 2022: International Agency Research on Cancer. https://gco.iarc.fr/today/online-analysis-table?v=2020&amp;mode=cancer&amp;mode_population=continents&amp;population=900&amp;populations=170&amp;key=asr&amp;sex=2&amp;cancer=39&amp;type=1&amp;statistic=5&amp;prevalence=0&amp;population_group=0&amp;ages_group%5B%5D=0&amp;ages_group%5B%5D=17&amp;group_cancer=1&amp;i</Citation></Reference><Reference><Citation>American Cancer Society  . What is ovarian cancer? - About ovarian cancer. Cancer.Org; 2018. pp. 1&#x2013;15.https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html</Citation></Reference><Reference><Citation>Chen J, Bae E, Zhang L, Hughes K, Parmigiani G, Braun D, et al. Penetrance of breast and ovarian c&#xe1;ncer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-oophorectomy: An updated meta-analysis. JNCI Cancer Spectr. 2020;4(4) doi: 10.1093/jncics/pkaa029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jncics/pkaa029</ArticleId><ArticleId IdType="pmc">PMC7353955</ArticleId><ArticleId IdType="pubmed">32676552</ArticleId></ArticleIdList></Reference><Reference><Citation>Catenacci D, Amico A, Nielsen S, Geynisman D, Rambo B, Carey G, et al. Tumor genome analysis includes germline genome: Are we ready for surprises? Int J Cancer. 2015;136(7):1559&#x2013;1567. doi: 10.1002/ijc.29128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29128</ArticleId><ArticleId IdType="pmc">PMC4303936</ArticleId><ArticleId IdType="pubmed">25123297</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright A, Bohlke K, Armstrong D, Bookman M, Cliby W, Coleman R, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol. 2016;143(1):3&#x2013;15. doi: 10.1016/j.ygyno.2016.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2016.05.022</ArticleId><ArticleId IdType="pmc">PMC5413203</ArticleId><ArticleId IdType="pubmed">27650684</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleridge S, Bryant A, Kehoe S, Morrison J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021;2021(7) doi: 10.1002/14651858.CD005343.pub6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005343.pub6</ArticleId><ArticleId IdType="pmc">PMC8406953</ArticleId><ArticleId IdType="pubmed">34328210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehoe S, Hook J, Nankivell M, Jayson G, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian c&#xe1;ncer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249&#x2013;257. doi: 10.1016/S0140-6736(14)62223-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)62223-6</ArticleId><ArticleId IdType="pubmed">26002111</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network  . Ovarian cancer (version 1.2023) https://www.nccn.org/login</Citation></Reference><Reference><Citation>Al Rawahi T, Lopes A, Bristow R, Bryant A, Elattar A, Chattopadhyay S, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2013(2) doi: 10.1002/14651858.CD008765.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD008765.pub2</ArticleId><ArticleId IdType="pmc">PMC6457850</ArticleId><ArticleId IdType="pubmed">23450588</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagotti A, Ferrandina M, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850) Int J Gynecol Cancer. 2020;30(11):1657&#x2013;1664. doi: 10.1136/ijgc-2020-001640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ijgc-2020-001640</ArticleId><ArticleId IdType="pubmed">33028623</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra M, Singh N, Ghatage P. Past, present, and future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in ovarian cancer. Cureus. 2021;13(6) doi: 10.7759/cureus.15563.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.15563</ArticleId><ArticleId IdType="pmc">PMC8272440</ArticleId><ArticleId IdType="pubmed">34277186</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt G, Oxman A, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383&#x2013;394. doi: 10.1016/j.jclinepi.2010.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.04.026</ArticleId><ArticleId IdType="pubmed">21195583</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso- Coello P, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. Chinese J Evidence-Based Med. 2008;9(1):8&#x2013;11. doi: 10.1136/bmj.39489.470347.AD.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39489.470347.AD</ArticleId></ArticleIdList></Reference><Reference><Citation>Healthcare Improvement Scotland  . SIGN GRADING SYSTEM 1999-2012. https://www.sign.ac.uk/assets/sign_grading_system_1999_2012.pdf</Citation></Reference><Reference><Citation>Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer. 2017;27(7):1534&#x2013;1542. doi: 10.1097/IGC.0000000000001041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IGC.0000000000001041</ArticleId><ArticleId IdType="pubmed">30814245</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergote I, Trop&#xe9; C, Amant F, Kristensen G, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943&#x2013;953. doi: 10.1056/NEJMoa0908806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0908806</ArticleId><ArticleId IdType="pubmed">20818904</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage W, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672&#x2013;705. doi: 10.1093/annonc/mdz062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdz062</ArticleId><ArticleId IdType="pubmed">31046081</ArticleId></ArticleIdList></Reference><Reference><Citation>Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo J, et al. SEOM clinical guideline in ovarian cancer (2020) Clin Transl Oncol. 2021;23(5):961&#x2013;968. doi: 10.1007/s12094-020-02545-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12094-020-02545-x</ArticleId><ArticleId IdType="pmc">PMC8058000</ArticleId><ArticleId IdType="pubmed">33515422</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, et al. The 2020 Japan Society of Gynecologic Oncology Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. J Gynecol Oncol. 2021;32(2):1&#x2013;20. doi: 10.3802/jgo.2021.32.e49.</Citation><ArticleIdList><ArticleId IdType="doi">10.3802/jgo.2021.32.e49</ArticleId><ArticleId IdType="pmc">PMC7930451</ArticleId><ArticleId IdType="pubmed">33650343</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuss A, Du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, et al. TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGOOVAR OP7) Int J Gynecol Cancer. 2019;29(8):1327&#x2013;1 31. doi: 10.1136/ijgc-2019-000682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ijgc-2019-000682</ArticleId><ArticleId IdType="pubmed">31420412</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and metaanalysis. Eur J Surg Oncol. 2019;45(3):301&#x2013;309. doi: 10.1016/j.ejso.2018.10.528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejso.2018.10.528</ArticleId><ArticleId IdType="pubmed">30786961</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Zhu Y, Liu C, Chao G, Cui R, Zhang Z. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: The meta-analysis. J Ovarian Res. 2019;12(1):1&#x2013;9. doi: 10.1186/s13048-019-0509-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13048-019-0509-1</ArticleId><ArticleId IdType="pmc">PMC6472063</ArticleId><ArticleId IdType="pubmed">30995948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Cho J, Lee E, Park S, Park S, Seol A, et al. Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis. Medicine. 2019;98(50):1&#x2013;9. doi: 10.1097/MD.0000000000018355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000018355</ArticleId><ArticleId IdType="pmc">PMC6922570</ArticleId><ArticleId IdType="pubmed">31852138</ArticleId></ArticleIdList></Reference><Reference><Citation>van Driel W, Koole S, Sikorska K. Schagen van Leeuwen J. Schreuder H. Hermans R, et al. Hyperthermic Intraperitoneal Chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230&#x2013;240. doi: 10.1056/NEJMoa1708618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1708618</ArticleId><ArticleId IdType="pubmed">29342393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim M, Chang S, Park B, Yoo H, Yoo C, Nam B, et al. Survival after Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in ovarian cancer: A randomized clinical trial. JAMA Surg. 2022;157(5):374&#x2013;383. doi: 10.1001/jamasurg.2022.0143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2022.0143</ArticleId><ArticleId IdType="pmc">PMC8908225</ArticleId><ArticleId IdType="pubmed">35262624</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergote I, Harter P, Chiva L. Hyperthermic Intraperitoneal Chemotherapy does not improve survival in advanced ovarian cancer. Cancer. 2019;125(4):594&#x2013;597. doi: 10.1002/cncr.32496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.32496</ArticleId><ArticleId IdType="pubmed">31967685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavou&#xe9; V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, et al. Part II. Drafted from the short text of the French guidelines entitled &#x201c;Initial management of patients with epithelial ovarian cancer&#x201d; developed by Francogyn, CNGOF, SFOG, Gineco-Arcagy and endorsed by INCa. (Systemic and intraperitoneal treatment, elderly) Gynecol Obstet Fertil Senol. 2019;47(2):111&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">30704955</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network  . Clinical N, Guidelines P, Guidelines N. Genetic / Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V2.2022. 2022. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</Citation></Reference><Reference><Citation>Hampel H, Bennett R, Buchanan A, Pearlman R, Wiesner G. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral indications for c&#xe1;ncer predisposition assessment. Genet Med. 2015;17(1):70&#x2013;87. doi: 10.1038/gim.2014.147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2014.147</ArticleId><ArticleId IdType="pubmed">25394175</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinopoulos P, Norquist B, Lacchetti C, Armstrong D, Grisham R, Goodfellow P, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(11):1222&#x2013;1245. doi: 10.1200/JCO.19.02960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.19.02960</ArticleId><ArticleId IdType="pmc">PMC8842911</ArticleId><ArticleId IdType="pubmed">31986064</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson M, Bernardini M, Sobel M, Kim R, McCuaig J, Allen L. No. 366-Gynaecologic Management of Hereditar y Breast and Ovarian Cancer. J Obstet Gynaecol Canada. 2018;40(11):1497&#x2013;1510. doi: 10.1016/j.jogc.2018.05.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jogc.2018.05.046</ArticleId><ArticleId IdType="pubmed">30473125</ArticleId></ArticleIdList></Reference><Reference><Citation>Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso M, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 2016;(5):v103&#x2013;v110. doi: 10.1093/annonc/mdw327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdw327</ArticleId><ArticleId IdType="pubmed">27664246</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence  . Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Clinical Guideline 164; Cardiff (UK): 2013. http://guidance.nice.org.uk/CG164</Citation></Reference><Reference><Citation>Scottish Intercollegiate Guidelines Network  . SIGN 135 - Management of epithelial ovarian cancer. 2013. http://www.sign.ac.uk</Citation></Reference><Reference><Citation>Gonz&#xe1;lez-Santiago S.Ram&#xf3;nCajal T, Aguirre E, Al&#xe9;s-Mart&#xed;nez J, Andr&#xe9;s R, Balma&#xf1;a J, et al. SEOM clinical guidelines in hereditary breast and ovarian cancer (2019) Clin Transl Oncol. 2020;22(2):193&#x2013;200. doi: 10.1007/s12094-019-02262-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12094-019-02262-0</ArticleId><ArticleId IdType="pubmed">31889241</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra H, Kowtal P, Mehra N, Pramank R, Sarin R, Rajkumar T, et al. Genetic counseling, testing, and management of HBOC in India: An expert consensus document from Indian Society of Medical and Pediatric Oncology. JCO Glob Oncol. 2020;6(6):991&#x2013;1008. doi: 10.1200/JGO.19.00381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JGO.19.00381</ArticleId><ArticleId IdType="pmc">PMC7392772</ArticleId><ArticleId IdType="pubmed">32628584</ArticleId></ArticleIdList></Reference><Reference><Citation>Pignata S, Scambia G, Katsaros D, Gallo C, Pujade- Lauraine E, De Placido S, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15(4):396&#x2013;405. doi: 10.1016/S1470-2045(14)70049-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)70049-X</ArticleId><ArticleId IdType="pubmed">24582486</ArticleId></ArticleIdList></Reference><Reference><Citation>SIGN 135 . Management of epithelial ovarian cancer. Key to evidence statements and grades of recommendations. 2013.</Citation></Reference><Reference><Citation>Vanderpuye V, Clemenceau V, Jr, Temin S, Aziz Z, Burke W, Cevallos N, et al. Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol. 2021;7(7):1032&#x2013;1066. doi: 10.1200/GO.21.00085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/GO.21.00085</ArticleId><ArticleId IdType="pmc">PMC8457806</ArticleId><ArticleId IdType="pubmed">34185571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirte H, Poon R, Yao X, May T, Ethier J, Petz L, et al. Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Crit Rev Oncol Hematol. 2021;(162):103324&#x2013;103324. doi: 10.1016/j.critrevonc.2021.103324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2021.103324</ArticleId><ArticleId IdType="pubmed">33862245</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473&#x2013;2483. doi: 10.1056/NEJMoa1104390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1104390</ArticleId><ArticleId IdType="pubmed">22204724</ArticleId></ArticleIdList></Reference><Reference><Citation>Perren T, Swart A, Pfisterer J, Ledermann J, Pujade- Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484&#x2013;2496. doi: 10.1056/NEJMoa1103799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1103799</ArticleId><ArticleId IdType="pubmed">22204725</ArticleId></ArticleIdList></Reference><Reference><Citation>Oza A, Cook A, Pfisterer J, Embleton A, Ledermann J, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol. 201516(8):928&#x2013;936. doi: 10.1016/S1470-2045(15)00086-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(15)00086-8</ArticleId><ArticleId IdType="pmc">PMC4648090</ArticleId><ArticleId IdType="pubmed">26115797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaaback K, Johnson N, Lawrie T. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;2016(2) doi: 10.1002/14651858.CD005340.pub4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005340.pub4</ArticleId><ArticleId IdType="pmc">PMC8602974</ArticleId><ArticleId IdType="pubmed">26755441</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495&#x2013;2505. doi: 10.1056/NEJMoa1810858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1810858</ArticleId><ArticleId IdType="pubmed">30345884</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Mart&#xed;n A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza M, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391&#x2013;2402. doi: 10.1056/NEJMoa1910962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1910962</ArticleId><ArticleId IdType="pubmed">31562799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray-Coquard I, Pautier P, Pignata S, P&#xe9;rol D, Gonz&#xe1;lez- Mart&#xed;n A, Berger R, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416&#x2013;2428. doi: 10.1056/NEJMoa1911361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1911361</ArticleId><ArticleId IdType="pubmed">31851799</ArticleId></ArticleIdList></Reference><Reference><Citation>Tew W, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, et al. PARP Inhibitors in the management of ovarian cancer: ASCO Guideline. J Clin Oncol. 2020;38(30):3468&#x2013;3493. doi: 10.1200/JCO.20.01924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.01924</ArticleId><ArticleId IdType="pmc">PMC8942301</ArticleId><ArticleId IdType="pubmed">32790492</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R, Leary A, Scott C, Serra V, Lord C, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606&#x2013;1622. doi: 10.1016/j.annonc.2020.08.2102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.08.2102</ArticleId><ArticleId IdType="pubmed">33004253</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti C, Fagotti A, Tombolini V, Scambia G, De Felice F. The role of secondary cytoreductive surgery in recurrent ovarian cancer: A systematic review and metaanalysis. Ann Surg Oncol. 2021;28(6):3258&#x2013;3263. doi: 10.1245/s10434-020-09226-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-020-09226-7</ArticleId><ArticleId IdType="pubmed">33067742</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman R, Spirtos N, Enserro D, Herzog T, Sabbatini P, Armstrong D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929&#x2013;1939. doi: 10.1056/NEJMoa1902626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1902626</ArticleId><ArticleId IdType="pmc">PMC6941470</ArticleId><ArticleId IdType="pubmed">31722153</ArticleId></ArticleIdList></Reference><Reference><Citation>Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385(23):2123&#x2013;2131. doi: 10.1056/NEJMoa2103294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103294</ArticleId><ArticleId IdType="pubmed">34874631</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ ENGOT-ov20. J Clin Oncol. 2020;38(15):6000&#x2013;6000. doi: 10.1200/JCO.2020.38.15_suppl.6000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2020.38.15_suppl.6000</ArticleId></ArticleIdList></Reference><Reference><Citation>Harter P, Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702&#x2013;1710. doi: 10.1245/s10434-006-9058-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-006-9058-0</ArticleId><ArticleId IdType="pubmed">17009163</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian W, Chi D, Sehouli J, Trop&#xe9; C, Jiang R, Ayhan A, et al. Ann Surg Oncol. 2012;19(2):597&#x2013;604. doi: 10.1245/s10434-011-1873-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-011-1873-2</ArticleId><ArticleId IdType="pubmed">21732142</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis J, Coakley N, Elit L, Mackay H. Systemic therapy for recurrent epithelial ovarian cancer: A clinical practice guideline. Curr Oncol. 2017;24(6):e540&#x2013;e546. doi: 10.3747/co.24.3824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3747/co.24.3824</ArticleId><ArticleId IdType="pmc">PMC5736494</ArticleId><ArticleId IdType="pubmed">29270064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29730979</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2171-8695</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria</Title><ISOAbbreviation>Farm Hosp</ISOAbbreviation></Journal><ArticleTitle>Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain.</ArticleTitle><Pagination><StartPage>95</StartPage><EndPage>102</EndPage><MedlinePgn>95-102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7399/fh.10904</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To estimate the economic impact of the introduction of olaparib&#xa0;in&#xa0; the Spanish National Health System as maintenance monotherapy&#xa0;in patients&#xa0; with BRCA-mutation positive high-grade serous ovarian cancer.</AbstractText><AbstractText Label="METHOD">A budget impact model was developed from the Spanish NHS&#xa0;perspective and a time horizon of 5 years for four treatment lines. The&#xa0;model included prevalent and incident patients estimated according to&#xa0;Spanish epidemiological data. Patients moved between treatment lines&#xa0;according to the progression-free survival and overall survival curves&#xa0; obtained&#xa0;from the respective clinical trials. Only direct costs (&#x20ac; 2017) were&#xa0;considered: pharmacological, administration, adverse effects and genetic&#xa0;tests. The robustness of the model was verified by a univariate&#xa0; sensitivity&#xa0;analysis.</AbstractText><AbstractText Label="RESULTS">The use of olaparib meant that, after 5 years, 6% fewer patients&#xa0;progressed to later lines compared to scenario without olaparib,&#xa0; remaining&#xa0;longer in the second line and delaying the initiation of subsequent&#xa0;lines. The total estimated budgetary impact ranged between &#x20ac; 1.6&#xa0; and&#xa0;&#x20ac; 5.4 million (1-5 years). The economic impact associated to the&#xa0; introduction&#xa0;of olaparib is partially offset by the lower cost of chemotherapy,&#xa0;related adverse events, and palliative care in patients with&#xa0; olaparib than&#xa0;in patients without it.</AbstractText><AbstractText Label="CONCLUSIONS">Olaparib as maintenance treatment in patients with BRCA-mutation positive high-grade serous ovarian cancer increases progression-free&#xa0; survival and delays the use of subsequent chemotherapy, with an&#xa0;budgetary&#xa0; impact for the Spanish National Health System of 5.4 million&#xa0;euros after 5 years.</AbstractText><CopyrightInformation>Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delgado-Ortega</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>AstraZeneca, Madrid. Laura.Delgado@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gin&#xe9;s Rubi&#xf3;</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmacy Service, University Hospital Son Espases.Palma de Mallorca, Baleares. jorge.gines@ssib.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;as de Espa&#xf1;a</LastName><ForeName>Maria Del Carmen</ForeName><Initials>MDC</Initials><AffiliationInfo><Affiliation>Medical Oncology Service, Son Espases University Hospital, Palma de Mallorca, Baleares. mariad.garcias@ssib.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carcedo</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Oblikue Consulting, Barcelona. david.carcedo@oblikue.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordero Puentes</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>AstraZeneca, Madrid. LuisAngel.Cordero@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moya de Alarc&#xf3;n</LastName><ForeName>Carlota</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AstraZeneca, Madrid. carlota.moya@astrazeneca.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Impacto econ&#xf3;mico de olaparib en el tratamiento de mantenimiento de mujeres con c&#xe1;ncer de ovario epitelial seroso de alto grado en reca&#xed;da, platino sensibles y con mutaci&#xf3;n BRCA en Espa&#xf1;a.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Farm Hosp</MedlineTA><NlmUniqueID>9440679</NlmUniqueID><ISSNLinking>1130-6343</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010793">Phthalazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>WOH1JD9AR8</RegistryNumber><NameOfSubstance UI="C531550">olaparib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018297" MajorTopicYN="N">Neoplasms, Cystic, Mucinous, and Serous</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010793" MajorTopicYN="N">Phthalazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Objetivo: Estimar el impacto econ&#xf3;mico de la introducci&#xf3;n de olaparib&#xa0;en el&#xa0; Sistema Nacional de Salud como monoterapia de mantenimiento en&#xa0;pacientes&#xa0; con c&#xe1;ncer de ovario seroso de alto grado y mutaci&#xf3;n BRCA.M&#xe9;todo: Se desarroll&#xf3; un modelo de impacto presupuestario desde la&#xa0; perspectiva&#xa0;del Sistema Nacional de Salud y un horizonte temporal de cinco a&#xf1;os&#xa0;a lo largo de cuatro l&#xed;neas de tratamiento. El modelo incluye pacientes&#xa0; prevalentes&#xa0;e incidentes estimadas a partir de datos epidemiol&#xf3;gicos espa&#xf1;oles.&#xa0; Las&#xa0;pacientes se mueven entre las l&#xed;neas de tratamiento en funci&#xf3;n de las curvas de&#xa0;supervivencia libre de progresi&#xf3;n y supervivencia global obtenidas de los&#xa0; respectivos&#xa0;ensayos cl&#xed;nicos. Solo se consideraron costes directos (&#x20ac; 2017):&#xa0; farmacol&#xf3;gicos,&#xa0;de administraci&#xf3;n, efectos adversos y test gen&#xe9;ticos. La&#xa0; robustez del&#xa0;modelo se ha comprobado a trav&#xe9;s de un an&#xe1;lisis de sensibilidad&#xa0; univariante.Resultados: El uso de olaparib conllev&#xf3; que, tras cinco a&#xf1;os, un 6% menos&#xa0;de&#xa0; pacientes progresaran a l&#xed;neas posteriores, en comparaci&#xf3;n al escenario&#xa0;sin&#xa0; olaparib, permaneciendo m&#xe1;s tiempo en segunda l&#xed;nea y retrasando el&#xa0;inicio de&#xa0; l&#xed;neas subsiguientes. El impacto presupuestario total estimado oscil&#xf3;&#xa0;entre 1,6 y&#xa0; 5,4 millones de euros (1-5 a&#xf1;os). Este impacto econ&#xf3;mico se ve&#xa0;parcialmente&#xa0; compensado por los costes de la quimioterapia, el manejo de sus&#xa0;efectos&#xa0; adversos y los cuidados paliativos, los cuales producen ahorros para&#xa0;el Sistema&#xa0; Nacional de Salud.Conclusiones: Olaparib como tratamiento de mantenimiento en pacientes&#xa0;con&#xa0; c&#xe1;ncer de ovario seroso de alto grado y mutaci&#xf3;n del gen&#xa0;BRCA aumenta la&#xa0; supervivencia libre de progresi&#xf3;n y retrasa la utilizaci&#xf3;n&#xa0;de quimioterapia&#xa0; posteriores, con un impacto presupuestario para el Sistema&#xa0;Nacional de Salud de&#xa0; 5,4 millones de euros tras 5 a&#xf1;o.</AbstractText><CopyrightInformation>Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29730979</ArticleId><ArticleId IdType="doi">10.7399/fh.10904</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>